[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
2019 Bio Top5 인터뷰
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
홍연희 (Yeonhee Hong)
조회 321  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
열기 Authors and Affiliations


Skeletal muscle atrophy is defined as a reduction of muscle mass caused by excessive protein degradation. However, the development of therapeutic interventions is still in an early stage. Although glucagon‐like peptide‐1 receptor (GLP‐1R) agonists, such as exendin‐4 (Ex‐4) and dulaglutide, are widely used for the treatment of diabetes, their effects on muscle pathology are unknown. In this study, we investigated the therapeutic potential of GLP‐1R agonist for muscle wasting and the mechanisms involved.

Mouse C2C12 myotubes were used to evaluate the in vitro effects of Ex‐4 in the presence or absence of dexamethasone (Dex) on the regulation of the expression of muscle atrophic factors and the underlying mechanisms using various pharmacological inhibitors. In addition, we investigated the in vivo therapeutic effect of Ex‐4 in a Dex‐induced mouse muscle atrophy model (20 mg/kg/day i.p.) followed by injection of Ex‐4 (100 ng/day i.p.) for 12 days and chronic kidney disease (CKD)‐induced muscle atrophy model. Furthermore, we evaluated the effect of a long‐acting GLP‐1R agonist by treatment of dulaglutide (1 mg/kg/week s.c.) for 3 weeks, in DBA/2J‐mdx mice, a Duchenne muscular dystrophy model.

Ex‐4 suppressed the expression of myostatin (MSTN) and muscle atrophic factors such as F‐box only protein 32 (atrogin‐1) and muscle RING‐finger protein‐1 (MuRF‐1) in Dex‐treated C2C12 myotubes. The suppression effect was via protein kinase A and protein kinase B signalling pathways through GLP‐1R. In addition, Ex‐4 treatment inhibited glucocorticoid receptor (GR) translocation by up‐regulating the proteins of GR inhibitory complexes. In a Dex‐induced muscle atrophy model, Ex‐4 ameliorated muscle atrophy by suppressing muscle atrophic factors and enhancing myogenic factors (MyoG and MyoD), leading to increased muscle mass and function. In the CKD muscle atrophy model, Ex‐4 also increased muscle mass, myofiber size, and muscle function. In addition, treatment with a long‐acting GLP‐1R agonist, dulaglutide, recovered muscle mass and function in DBA/2J‐mdx mice.

GLP‐1R agonists ameliorate muscle wasting by suppressing MSTN and muscle atrophic factors and enhancing myogenic factors through GLP‐1R‐mediated signalling pathways. These novel findings suggest that activating GLP‐1R signalling may be useful for the treatment of atrophy‐related muscular diseases.

Keywords : Skeletal muscle atrophy, GLP‐1R agonists, Dexamethasone, Glucocorticoid receptor, Chronic kidney disease, Duchenne muscular dystrophy

- 형식: Research article
- 게재일: 2019년 04월 (BRIC 등록일 2019-04-26)
- 연구진: 국내연구진태극기
경제적 의사결정의 개별과정을 동질한 성격의 뉴런으로 구현하기[Neuron]
발표: 유승범 (University of Minnesota)
일자: 2020년 1월 29일 (수) 오전 10시 (한국시간)
언어: 영어
참석자 접수신청하기
유전자 편집 기술을 활용한 도시농업 적합 작물 개발[Nat. Biotechnol.]
발표: 권춘탁 (Cold Spring Harbor Labor...)
일자: 2020년 2월 19일 (수) 오전 11시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
홍연희 님 전체논문보기 >
전희숙 (가천대학교 약학과)
Google (by Yeonhee Hong)
Pubmed (by Yeonhee Hong)
프리미엄 Bio일정 Bio일정 프리미엄 안내
2020 서경배과학재단 신진과학자 연구지원 프로그램
2020 서경배과학재단 신진과학자 연구지원 프로그램
날짜: 2020.03.31
주관: 서경배과학재단
[BRIC Webinar]경제적 의사결정의 개별과정을 동질한 성격의 뉴런으로 구현하기[Neuron]
[무료/ 취업연계]바이오QC 실무과정 8기 모집
[무료/ 취업연계]바이오QC 실무과정 8기 모집
사전접수: ~2020.02.10
날짜: 2020.03.02~06.12
장소: 성남시 분당구 황새울로
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS